TransCode Secures Next-Generation Oncolytic Immunotherapy License – Eyes Multi-Billion Dollar Bladder Cancer Market
TransCode Therapeutics (RNAZ) announces an exclusive license for advanced cancer immunotherapy tech from Unleash, targeting hard-to-treat bladder cancer and more, in an all-stock deal to expand their pipeline.
